The Yangtze River Pharmaceutical Group, whose headquarters is in Taizhou city, owns over 20 subsidiaries. [Photo/WeChat account: weigg6666]
The Yangtze River Pharmaceutical Group – based in Taizhou city in East China's Jiangsu province – was recently recognized as a national-level intelligent manufacturing pilot area in the traditional Chinese medicine sector, becoming the first of its kind in the province.
The assessment work was conducted by the Administration of Market Regulation of Jiangsu Province, under the auspices of the Standardization Administration of China.
The company has invested more than 100 million yuan ($14.48 million) in the intelligent manufacturing of traditional Chinese medicine and it has hired and trained many national-level standardization tech people.
Focusing on the standardization of key manufacturing links, it promoted an informatization applications system to boost the modern upgrading of traditional Chinese medicine manufacturing.
It also put together collected and collated 2,556 standards – and five standards for traditional Chinese medicinal materials were included in the European Pharmacopoeia.
By adopting standardization, it is understood that production processes became more controllable and the medicine quality more stable.